NeuroNOS, a pioneering biopharmaceutical company focused on developing transformative treatments for Autism Spectrum Disorder (ASD) and other complex neurological conditions, including Alzheimer’s ...
BDC-4182 on track to start a clinical trial in gastric cancer in second quarter 2025 BDC-3042 Phase 1 clinical trial fully enrolled the highest dose cohort with no dose-limiting toxicities (DLTs), ...
OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced it was selected as one of the ...
On July 21, 2023, AEON completed the Merger with AEON Biopharma Sub, Inc. (“Old AEON”), with Old AEON surviving the merger as a wholly-owned subsidiary of the Company, the accounting acquirer. The ...
Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
As of December 31, 2024, Aura had cash and cash equivalents and marketable securities totaling $151.1 million. The Company believes its current cash and cash equivalents and marketable securities are ...
Robust balance sheet with cash, cash equivalents and investments of $185.4 million as of December 31, 2024, is expected to fund operations at least through end of 2026 SAN DIEGO, March 24, 2025 (GLOBE ...
Net Loss: The net loss attributable to Serina for the year ended December 31, 2024 was $11.1 million, or $ (1.51) per basic and diluted share, compared to net income of $5.3 million, or $2.36 per ...
Full Year 2024 Financial Results Revenue from Continuing Operations was $20.2 million for 2024, an increase of 181% compared to $7.2 million in 2023.
La gestion fine des charges opérationnelles, combinée à la progression des ventes, permet au résultat d’exploitation de s’apprécier de + 3,6 M€ pour s’établir à - 0,9 M€ en 2024, contre une perte de 4 ...
As a result, the net loss improved significantly to €3.9 million in FY 2024, compared with a loss of €6.5 million in FY 2023. Adjusted for the exceptional expense related to the Negma agreement, the ...
PatchMD, a leader in innovative nutrient delivery systems, proudly announces the launch of its new Mito Cocktail Patch, ...
Better Choice Company (NYSE: BTTR) (“Better Choice” or “the Company”), a pet health and wellness company, today announced that SRx Health’s management team will be presenting at the 2025 Bloom Burton ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback